CordovaCann (LVRLF) EBITDA Margin (2009 - 2019)

CordovaCann (LVRLF) recorded quarterly EBITDA Margin of 8179.19% in Q2 2019, up 149.28% quarter-over-quarter from 16598.38% in Q1 2019.

CordovaCann (LVRLF) EBITDA Margin (2009 - 2019) Analysis & Trends

CordovaCann's EBITDA Margin history runs 3 years deep, the most recent figure standing at 8179.19% for Q2 2019.

In Q2 2019, EBITDA Margin changed N/A year-over-year to 8179.19%; the TTM figure through Jun 2019 stood at 1718148.01% (changed N/A YoY), while the FY2025 annual figure was 0.76%, up 310.0% from the prior year.
EBITDA Margin was 8179.19% for Q2 2019 at CordovaCann, up from 16598.38% in the prior quarter.
In the past five years, EBITDA Margin ranged from a high of 8179.19% in Q2 2019 to a low of 21408.52% in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	16.37%
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	36.83%
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	41.69%
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	-1.01%
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	22.74%
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	22.39%
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	-170.35%
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	-16.25%
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	21.55%
10	CordovaCann	-	-	-	-

Download Data